Phase 3 Study Comparing Temozolomide Plus Lomustine Versus Temozolomide Alone for Newly Diagnosed MGMT Methylated Glioblastoma in Adults Aged 18 to 70
Led by Vastra Gotaland Region · Updated on 2026-04-13
200
Participants Needed
20
Research Sites
104 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating a treatment approach for patients with newly diagnosed glioblastoma that have a methylated MGMT promoter, a specific genetic feature of the tumor. This phase 3 clinical trial compares the standard chemotherapy drug Temozolomide TMZ alone to a combination of Temozolomide plus Lomustine LOM. The study aims to determine if adding Lomustine improves survival rates, progression-free survival, safety, quality of life, and cognitive function.
Participants are randomly assigned to one of two groups. The control group receives Temozolomide during and after radiation therapy. The experimental group receives both Temozolomide and Lomustine starting on the first day of radiation. Lomustine and Temozolomide are given as oral pills in cycles, with Lomustine cycles lasting 42 days for a total of six cycles over about nine months, while Temozolomide cycles last 28 days with six cycles over about 8.5 months. Radiation therapy is given concurrently with the start of chemotherapy in both groups.
During the study, participants will have regular assessments including survival monitoring, tumor progression checks, and safety evaluations for side effects. Quality of life and detailed neurocognitive tests measuring memory, attention, motor skills, and reaction times are conducted at the start, end of radiotherapy, and every 24 weeks for up to 36 months. Adverse events are tracked from randomization until death or three years of follow-up. The study involves close monitoring to understand the long-term effects and benefits of adding Lomustine to standard treatment.
CONDITIONS
Brief Title
Lomustine in Addition to Standard of Care in Patients With MGMT Methylated Glioblastoma
Research Team
A
Asgeir S Jakola, MD, PhD
A
Annika Malmström, MD. PhD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Newly diagnosed glioblastoma or gliosarcoma, IDH wild type
Methylated MGMT promoter
World Health Organization performance status 0 to 2
Age between 18 and 70 years
You will not qualify if you...
Previous malignancy within the last 3 years or malignancy treated non-curatively
Previous chemotherapy or radiotherapy involving the head
Off-protocol tumor-specific treatment
Serious comorbid conditions
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Treatment
Duration - 8.5 to 9 months
Participants receive treatment with either temozolomide plus lomustine or standard temozolomide therapy. Treatment begins on day 1 of radiotherapy and includes multiple cycles depending on the assigned arm.
6 treatment cycles with visits according to 28- or 42-day cycles depending on treatment arm
Follow-up
Duration - Up to 36 months
Participants are monitored for survival, disease progression, quality of life, neurocognition, and adverse events for up to 36 months after treatment starts.
Assessments at baseline, week 6, and every 24 weeks thereafter
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Phase 1 Study of Lutetium-177-PSMA-617 Radiotherapy with Temozolomide for Adults with IDH Wild Type Gliomas
Study of Long-Term Survivors and Controls in Metastatic Pancreatic, Glioblastoma, and Small Cell Lung Cancers to Identify New Treatment Targets
Randomized Trial of Continuous Glucose Monitoring Versus Standard Monitoring for Blood Sugar Control in Adults with Glioblastoma
Study of DB107-RRV and DB107-FC with Radiation Therapy, With or Without Temozolomide, in Newly Diagnosed High Grade Glioma Patients
Evaluating ERAS-801 Oral Treatment for Adults with Resectable EGFR-Positive Grade IV Glioblastoma or Gliosarcoma in a Phase Ib Trial
Study of Atorvastatin Combined With Temozolomide to Treat Glioblastoma with High EGFR Expression
Phase II Trial Evaluating Safety and Effectiveness in Adults 18 to 60 Years Old
Open-label Phase 1b Study Evaluating Safety and Tolerability of Eflornithine Plus Temozolomide
in Adults With Newly Diagnosed Glioblastoma or Astrocytoma
Phase 2 Study of G-CSF to Protect Brain Structure and Function After Standard Chemoradiation in Adults With Newly Diagnosed MGMT-Methylated Glioblastoma
Study of GI-102 Alone or With Pembrolizumab Before Surgery in Adults With Recurrent or Progressive IDH Wildtype Glioblastoma and Grade 4 Astrocytoma
Advanced Imaging Techniques to Improve Assessment of Tumor Activity in Newly Diagnosed Glioblastoma The GABLE Trial
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial.
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.
Health-related quality of life and neurocognitive functioning with lomustine-temozolomide versus temozolomide in patients with newly diagnosed, MGMT-methylated glioblastoma (CeTeG/NOA-09): a randomised, multicentre, open-label, phase 3 trial.
Johannes Weller, Theophilos Tzaridis, Frederic Mack...
Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial.